Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression

Table 1 The expression of IFNGR1 and IFNGR2 in several cancer types

Cancer type	IFNGR1 expression	IFNGR2 expression
Bladder urothelial carcinoma	No change	Upregulated
Breast invasive carcinoma	Downregulated	Upregulated
Cholangiocarcinoma	Upregulated	Upregulated
Colon adenocarcinoma	Downregulated	Downregulated
Esophageal carcinoma	Upregulated	Upregulated
Glioblastoma multiforme	Upregulated	Upregulated
Head and neck squamous cell carcinoma	Upregulated	Upregulated
Kidney chromophobe	Downregulated	Downregulated
Kidney renal clear cell carcinoma	Upregulated	Upregulated
Kidney renal papillary cell carcinoma	Upregulated	Upregulated
Liver hepatocellular carcinoma	Upregulated	Upregulated
Lung adenocarcinoma	Downregulated	Upregulated
Lung squamous cell carcinoma	Downregulated	Upregulated
Pancreatic adenocarcinoma	Downregulated	No change
Prostate adenocarcinoma	No change	Upregulated
Rectum adenocarcinoma	Downregulated	No change
Skin cutaneous melanoma	Downregulated	No change
Stomach adenocarcinoma	Upregulated	Upregulated
Thyroid carcinoma	No change	Upregulated
Uterine corpus endometrial carcinoma	Downregulated	Upregulated

Of 35 cancer types reported from the University of ALabama at Birmingham CANcer data analysis Portal, 20 cancers display changes, stadistically significant (P < 0.05), in the expression of IFNGR1 and/or IFNGR2.